AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.

Joel E. Gallant

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume15
Issue number4
StatePublished - 2003
Externally publishedYes

Fingerprint

Dideoxynucleosides
Reverse Transcriptase Inhibitors
Lamivudine
Zidovudine
CD4 Lymphocyte Count
Combination Drug Therapy
Viral Load
Nucleosides
HIV Infections
Clinical Trials
Trizivir

Cite this

@article{b1eb9a8217bf4addbc76937392f3cb04,
title = "AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.",
author = "Gallant, {Joel E.}",
year = "2003",
language = "English (US)",
volume = "15",
pages = "1--2",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "4",

}

TY - JOUR

T1 - AACTG A5095, Trizivir, and the role of all-nucleoside regimens

T2 - an editorial.

AU - Gallant, Joel E.

PY - 2003

Y1 - 2003

UR - http://www.scopus.com/inward/record.url?scp=0642307097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642307097&partnerID=8YFLogxK

M3 - Article

C2 - 14696559

AN - SCOPUS:0642307097

VL - 15

SP - 1

EP - 2

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 4

ER -